News Headlines
-
LSL Pharma Group Enters Into Binding Agreement To Acquire Quebec Competitor
5/6/2024
LSL PHARMA GROUP INC. (TSXV: LSL) ("the Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce that it has entered into a binding Letter of Intent ("LOI") to acquire profitable privately held, Quebec-based competing contract drug manufacturer ("CDMO") specialized in the formulation, production, and marketing of natural products ("Target Co") . Target Co. and its shareholders are at arm’s length from LSL Pharma.
-
Grand River Aseptic Manufacturing Expands Syringe And Cartridge Capacity With New 150,000 sq. ft. Syringe And Cartridge Filling Center
5/6/2024
Grand River Aseptic Manufacturing (“GRAM”), a leading sterile injectable contract manufacturer of biologics, small molecules, and vaccines, announces its third world-class facility in five years.
-
Wacker Expands Production Capacity For Biopharmaceuticals In San Diego
5/6/2024
As part of its growth strategy for the BIOSOLUTIONS life-science division, WACKER is increasing capacities in the field of biopharmaceuticals for advanced therapies.
-
Akoya Biosciences Opens Operations And Manufacturing Center Of Excellence In Marlborough, Massachusetts
5/6/2024
Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms.
-
Kindeva Drug Delivery Invests In Second Manufacturing Line For Greener Inhalers At UK Manufacturing Site
5/6/2024
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.
-
Alkermes plc Completes Sale Of Athlone, Ireland Facility To Novo Nordisk
5/2/2024
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
-
Charles River Launches Viral Vector Reference Materials To Streamline The Transition To GMP
5/2/2024
Charles River Laboratories International, Inc. today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
-
Multiply Labs And Wilson Wolf Corporation Collaborate To Automate G-Rex Bioreactor For Cell Therapy Manufacturing
5/2/2024
Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf, an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex bioreactors.
-
ProPharma And PBL Launch Innovative Cell & Gene Therapy Manufacturing Device
5/2/2024
ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, today announced that in partnership with PBL, it developed an enclosed, fully automated cell factory device, the Cell Factory Box (CF Box).
-
PCI Pharma Services Begins Installation Of Sterile Fill-Finish And Lyophilization Line As Part Of $100M New Facility Expansion
5/2/2024
PCI Pharma Services, (“PCI”) a world leading global contract development and manufacturing organization (CDMO), has begun installation of key equipment for its newest sterile fill-finish facility on the company’s Bedford, NH campus.